Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMYDA TICA-MI pharmacodynamic study of early vs delayed ticagrelor during cangrelor in STEMI PCI
2024-511944-18-01Phase 4Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Maggiore della Carità
- Start
- Aug 2024
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ticagrelor and cangrelor in acute ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Maggiore della Carità. Primary endpoint: High platelet reactivity incidence after cangrelor interruption. Started Aug 2024; status: completed.
02
Drugs
ticagrelorcangrelor
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on 2024-511944-18-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511944-18-01.